SCHEMBL14873196

SCHEMBL14873196

CNC(=O)CC(=O)N(C)c1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.44
GAA P10253 2/20 0.42
ALDH1A1 P00352 5/20 0.41
TSHR P16473 1/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
POLB P06746 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK1 P28482 1/20 0.38
ALPL P05186 1/20 0.37
ALPI P09923 1/20 0.37
ALPG P10696 1/20 0.37
KMT2A Q03164 3/20 0.36
GPBAR1 Q8TDU6 1/20 0.36
MEN1 O00255 2/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA5A P35218 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13619742 0.84 ALDH1A1 (0.42) TP53ALDH1A1TSHRDDB1CRBN
SCHEMBL10224328 0.83 ALDH1A1 (0.43) TP53GAAALDH1A1TSHRDDB1
SCHEMBL307587 0.83 ALDH1A1 (0.43) TP53GAAALDH1A1TSHRDDB1
SCHEMBL10172492 0.83 LMNA (0.46) TP53GAAALDH1A1TSHRDDB1
SCHEMBL23723586 0.82 ALDH1A1 (0.44) TP53GAAALDH1A1TSHRDDB1
SCHEMBL14839607 0.82 ALDH1A1 (0.42) TP53GAAALDH1A1TSHRDDB1
SCHEMBL308491 0.81 TP53 (0.46) TP53ALDH1A1TSHRDDB1CRBN
SCHEMBL10289214 0.80 KDM4E (0.46) TP53GAAALDH1A1TSHRPOLB
SCHEMBL13684202 0.80 ALDH1A1 (0.47) TP53GAAALDH1A1TSHRDDB1
SCHEMBL11339370 0.80 ALDH1A1 (0.44) TP53GAAALDH1A1TSHRDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183254-B1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2017-06-21 EP disclosed
US-9018378-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2015-04-28 US disclosed
US-8907091-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8906852-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-12-09 US disclosed
US-8846927-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-09-30 US disclosed
US-8569503-B2 Processes and intermediates for preparing fused heterocyclic kinase inhibitors METHYLGENE INC. (CA) 2013-10-29 US disclosed
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-06-27 US disclosed
US-20130096088-A1 Inhibitors of Protein Tyrosine Kinase Activity METHYLGENE INC. (CA) 2013-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET TP53 476/4885GAA 764/4885ALDH1A1 3139/4885
US-20130096088-A1 Inhibitors of Protein Tyrosine Kinase Activity KDR, FLT1, FLT4 TP53 573/4885GAA 677/4885ALDH1A1 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.